Publications by Stephan Wullschleger

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Stephan Wullschleger

Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most pa-tients respond transiently at best, highlighting the importance of understanding mechanisms underlying resistance. Herein, we evaluated the effects o ...

CELL PRESS2023

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells

Douglas Hanahan, Mélanie Louise Tichet, Stephan Wullschleger, Petra Catalina Schwalie, Maria Karagianni

Expansion and differentiation of antigen-experienced PD-1(+)TCF-1(+) stem-like CD8(+) T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade(1-4). Hashimoto et al. have shown that, in chronic infections, administr ...

NATURE PORTFOLIO2022

Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression

Douglas Hanahan, Krisztian Homicsko, Mohammad Sadegh Saghafinia, Stephan Wullschleger, Iacovos Michael, Giovanni Ciriello

Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics ap ...

AMER ASSOC CANCER RESEARCH2021

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity

Douglas Hanahan, Mélanie Louise Tichet, Stephan Wullschleger

AMER ASSOC CANCER RESEARCH2021

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers

Douglas Hanahan, Nadine Fournier, Mélanie Louise Tichet, Melody Swartz, Stephan Wullschleger, Gabriele Galliverti

Cancers induced by human papillomaviruses (HPV) should be responsive to immunotherapy by virtue of expressing the immunogenic oncoproteins E6/E7. However, advanced forms of cervical cancer, driven by HPV, are poorly responsive to immune response-enhancing ...

AMER ASSOC CANCER RESEARCH2020

A personalised approach for anti-GITR-based immunotherapy in preclinical models of pancreatic ductal adenocarcinoma

Douglas Hanahan, Mélanie Louise Tichet, Anguraj Sadanandam, Stephan Wullschleger

OXFORD UNIV PRESS2019

Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice

Douglas Hanahan, Mélanie Louise Tichet, Melody Swartz, Stephan Wullschleger, Gabriele Galliverti, Sylvie Hauert

Treatment of patients bearing human papillomavirus (HPV)-related cancers with synthetic long-peptide (SLP) therapeutic vaccines has shown promising results in clinical trials against premalignant lesions, whereas responses against later stage carcinomas ha ...

AMER ASSOC CANCER RESEARCH2018

A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

Douglas Hanahan, Anguraj Sadanandam, Stephan Wullschleger, Ismaël Wafy

Seeking to assess the representative and instructive value of an engineered mouse model of pancreatic neuroendocrine tumors (PanNET) for its cognate human cancer, we profiled and compared mRNA and miRNA transcriptomes of tumors from both. Mouse PanNET tumo ...

Amer Assoc Cancer Research2015

A colorectal cancer classification system that associates cellular phenotype and responses to therapy

Douglas Hanahan, Krisztian Homicsko, Anguraj Sadanandam, Stephan Wullschleger

Colorectal cancer (CRC) is a major cause of cancer mortality. Whereas some patients respond well to therapy, others do not, and thus more precise, individualized treatment strategies are needed. To that end, we analyzed gene expression profiles from 1,290 ...

Nature Publishing Group2013

Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation

Anguraj Sadanandam, Stephan Wullschleger

BACKGROUND: Our earlier reports demonstrated that membrane-bound semaphorin 5A (SEMA5A) is expressed in aggressive pancreatic cancer cells and tumours, and promotes tumour growth and metastasis. In this study, we examine whether (1) pancreatic cancer cells ...

Nature Publishing Group2012